|
Orthologous residues
|
|
NMDAR2C (human): S1081‑p, NMDAR2C (mouse): S1084‑p, NMDAR2C (rat): S1083‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
pharmacological activator of upstream enzyme
|
|
|
KINASE
|
Akt1 (human)
|
transfection of dominant-negative enzyme, transfection of constitutively active enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
IGF-1
|
|
|
|
increase
|
|
|
wortmannin
|
IGF-1
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
14-3-3 epsilon (rat)
|
|
Induces
|
|
|
yeast two-hybrid, co-immunoprecipitation
|
|